Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 13/20 | 0.54 |
| ▸ | MAOA | P21397 | 11/20 | 0.54 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.53 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3910083 | 0.86 | MAOB (0.71) | ACHEMEN1RAB9AKMT2AMAOB | |
| SCHEMBL17260692 | 0.80 | CA12 (0.56) | MEN1KMT2AMAOBMAOAKDM1A | |
| SCHEMBL17268194 | 0.80 | IL4I1 (0.56) | MEN1KMT2AMAOBMAOA | |
| SCHEMBL7402955 | 0.78 | MAOB (0.70) | ACHEMEN1KMT2AMAOBKDM1A | |
| SCHEMBL10503336 | 0.75 | MAOB (0.67) | ACHEMEN1KMT2AMAOBMAOA | |
| SCHEMBL16963882 | 0.74 | NOS1 (0.59) | MEN1KMT2A | |
| SCHEMBL17260660 | 0.73 | NFE2L2 (0.48) | KDM1A | |
| SCHEMBL7424114 | 0.72 | ACHE (1.00) | ACHEMEN1RAB9AKMT2AMAOB | |
| SCHEMBL8112791 | 0.71 | NOS1 (0.56) | MEN1KMT2A | |
| Coixol SCHEMBL29389732 | 0.71 | NOS1 (0.61) | MEN1RAB9AKMT2AMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10226452-B2 | Benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-03-12 | — | — | US | disclosed |
| US-10226452-B2 | Benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-03-12 | — | — | US | disclosed |
| US-20170182010-A1 | BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-06-29 | — | — | US | disclosed |
| US-20170182010-A1 | BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-06-29 | — | — | US | disclosed |
| WO-2015173168-A1 | BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2015-11-19 | — | — | WO | disclosed |
| WO-2015173168-A1 | BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2015-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10226452-B2 | Benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments | ASAH1, ASAH2, ACER2 | ACHE 945/4885MEN1 4313/4885RAB9A 3598/4885 |
| US-20170182010-A1 | BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | ASAH1, ASAH2, ACER2 | ACHE 945/4885MEN1 4313/4885RAB9A 3598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.